Innate Pharma (IPHA) Stock Statistics & Valuation Metrics

Innate Pharma has a market cap or net worth of $151.91M. The enterprise value is $96.56M.

Innate Pharma has 83.83M shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -8.25%.

The current PE Ratio of Innate Pharma is -26.92. Innate Pharma’s PEG ratio is 0.29.

In the last 12 months, Innate Pharma had revenue of $33.79M and earned -$34.05M in profits. Earnings per share was -$0.43.

In the last 12 months, operating cash flow was -$18.06M and capital expenditures -$325.00K, giving a free cash flow of -$18.38M billion.

Innate Pharma pays an annual dividend of , resulting in a dividend yield of

Innate Pharma upcoming earnings date is Sep 17, 2025, Before Open.

Innate Pharma as a current ratio of 3.73, with Debt / Equity ratio of 0.77

In the past 12 months, Innate Pharma has paid -$9.75M in taxes.

Innate Pharma EV to EBITDA ratio is -94.12, with an EV/FCF ratio of -4.96.

Innate Pharma has $91.80M in cash and marketable securities with $35.50M in debt, giving a net cash position of -$56.30M billion.

Gross margin is -7.94%, with operating margin of -24.41%, and net profit margin of -14.59%.

The average price target for Innate Pharma is $11.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy